They noted that a phase I trial of olaparib in combination with an ATM inhibitor known as AZD0156 is currently ongoing in patients with solid tumors. (cancernetwork.com)
A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (vicc.org)
The new study is also the first to identify which genetic mutations prostate cancers use to resist treatment with olaparib. (sciencedaily.com)